Next Step: Targeting Neurological Disorders and Cancer Treatment?!

撰文GlobalBio & Investment
日期2023-12-01
Moderna Co-founder and Alnylam Senior Vice President: Witnessing the Potential of Nucleic Acid Therapy in the Pandemic! Next Step: Targeting Neurological Disorders and Cancer Treatment?!
【Editor's Choice | Stories behind #BIO2023
Moderna Co-founder and Alnylam Senior Vice President: Witnessing the Potential of Nucleic Acid Therapy in the Pandemic! Next Step: Targeting Neurological Disorders and Cancer Treatment?!

The BIO 2023 International Convention is set to kick off on 6th June in Boston. On the eve of the event, the Development Center for Biotechnology (#DCB) and the Monte Jade New England (#MJNE) co-hosted the "2023 Taiwan Biotech Forum." They invited prominent figures such as Robert S. Langer, Co-founder of Moderna, and Muthiah Manoharan, Senior Vice President of Alnylam, to share the potential and trends of nucleic acid therapy, as well as the stories behind the development of these therapies.

Moderna Co-founder: 200 Failures Led to Breakthrough in Nucleic Acid Delivery Technology! Witnessing the Potential of RNA in the COVID-19 Pandemic.

Alnylam Senior Vice President: The Next Step in Nucleic Acid Therapy—Neurological Disorders and Cancer. Treatment!

Let's delve into their stories.

To learn more about stories behind #BIO2023, please visit #GlobalBio:
https://lnkd.in/gr79xrjq